Malaria Roadmap Announced

Researchers should aim to develop a vaccine by 2030 that can reduce malaria cases by 75 percent and eventually eliminate the disease, according to a new roadmap launched this week.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

False-colored electron micrograph of a sporozoite migrating through the cytoplasm of midgut epitheliaWIKIMEDIA, IMAGE BY UTE FREVERT; FALSE COLOR BY MARGARET SHEARTo successfully eliminate malaria, which currently causes an estimated 660,000 deaths each year, researchers must develop vaccines that reduce cases by 75 percent, a new roadmap released Thursday (November 14) suggests.

“Safe, effective, affordable vaccines could play a critical role in defeating malaria,” Robert Newman, director of the World Health Organization’s Global Malaria Programme, said in a press release. “Despite all the recent progress countries have made, and despite important innovations in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high.”

The 2013 Malaria Vaccine Technology Roadmap, launched today at the annual conference of the American Society of Tropical Medicine & Hygiene in Washington, DC, and announced in The Lancet, is an update to a 2006 plan that focused on a Plasmodium falciparum vaccine for children in sub-Saharan Africa by 2015—a goal that very well may be met by GlaxoSmithKline’s RTS,S vaccine candidate, which last month scored high marks for protecting children ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours